{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:52:11Z","timestamp":1791280331471,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":1835,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004388","name":"Cephalon","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GSK"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.breast.2014.06.004","type":"journal-article","created":{"date-parts":[[2014,7,14]],"date-time":"2014-07-14T18:15:16Z","timestamp":1405361716000},"page":"526-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":171,"title":["Current and future role of neoadjuvant therapy for breast cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Michael","family":"Untch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Paepke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2014.06.004_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-008-0050-1","article-title":"Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902","volume":"115","author":"van Nes","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2014.06.004_bib2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-011-1347-z","article-title":"Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms","volume":"128","author":"Kravchenko","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2014.06.004_bib3","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of national surgical adjuvant breast and Bowel Project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib5","series-title":"Neoadjuvant (primary) systemic therapy","author":"Bauerfeind","year":"2014"},{"key":"10.1016\/j.breast.2014.06.004_bib6","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local- regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2000.18.3.584","article-title":"Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors: the International Breast Cancer Study Group","volume":"18","author":"Colleoni","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.breast.2014.06.004_bib9","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27","volume":"30","author":"Mamounas","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1023\/A:1013128213451","article-title":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-010-1228-x","article-title":"Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials","volume":"125","author":"von Minckwitz","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2014.06.004_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdn323","article-title":"Preoperative therapy: what, when and for whom","volume":"19","author":"von Minckwitz","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2014.06.004_bib14","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1200\/JCO.2004.09.062","article-title":"Breast conserving therapy after neoadjuvant chemotherapy: the M.D. Anderson Cancer Center experience","volume":"22","author":"Chen","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib15","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.23068","article-title":"Placement of radiopaque clips for tumor localisation in patients undergoing neoadjuvant chemotherapy and breast conservation therapy","volume":"110","author":"OH","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2014.06.004_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2014.06.004_bib17","unstructured":"NCCN Guidelines Version 3.2014 Invasive Breast Cancer http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf [accessed 24.06.14]."},{"key":"10.1016\/j.breast.2014.06.004_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib19","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2014.06.004_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2002.20.1.17","article-title":"Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation","volume":"20","author":"Buchholz","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2014.06.004_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/030089161209800502","article-title":"Should radiotherapy after primary systemic therapy be administered with the same recommendations made for operable breast cancer patients who receive surgery as first treatment? A critical review","volume":"98","author":"Allis","year":"2012","journal-title":"Tumori"},{"key":"10.1016\/j.breast.2014.06.004_bib22","article-title":"IOERT as anticipated tumor bed boost during breast conserving surgery after neoadjuvant chemotherapy in LABC \u2013 Results of a case series after 5-year follow-up","author":"Fastner","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2014.06.004_bib23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2011.41.3161","article-title":"Defining the Benefits of neoadjuvant chemotherapy for breast cancer","volume":"30","author":"Schott","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib25","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/bcr3384","article-title":"HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer","volume":"15","author":"Denkert","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"30","key":"10.1016\/j.breast.2014.06.004_bib26","article-title":"Prognostic and predictive impact of Ki- 67 before and after neoadjuvant chemotherapy on pCR and survival: results of the GeparTrio trial","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib27","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2- positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"30","author":"Wolmark","year":"2001","journal-title":"J\u00a0Natl Cancer Inst Monographs"},{"key":"10.1016\/j.breast.2014.06.004_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2014.06.004_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2014.06.004_bib31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jamcollsurg.2009.01.035","article-title":"Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial","volume":"208","author":"Olson","year":"2009","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.breast.2014.06.004_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00280-008-0735-5","article-title":"Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer","volume":"63","author":"Seo","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.breast.2014.06.004_bib33","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib34","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes \u2013 dealing with the diversity of breast cancer. highlights of the st. gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib35","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib36","unstructured":"FDA guidance pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. online source: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM305501.pdf."},{"issue":"24 Suppl.\u00a03","key":"10.1016\/j.breast.2014.06.004_bib37","article-title":"Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients \u2013 result of the GeparTrio trial","volume":"71","author":"von Minckwitz","year":"2011","journal-title":"Cancer Res"},{"issue":"24, Suppl.\u00a03","key":"10.1016\/j.breast.2014.06.004_bib38","article-title":"Neoadjuvant Chemotherapy in the very young\u00a035 years of age or younger","volume":"72","author":"Loibl","year":"2012","journal-title":"Cancer Res"},{"issue":"24 Suppl.\u00a03","key":"10.1016\/j.breast.2014.06.004_bib39","article-title":"pCR as a Surrogate in HER-2-positive Patients Treated with Trastuzumab","volume":"71","author":"Loibl","year":"2011","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.breast.2014.06.004_bib40","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathological complete response after neoadjuvant chemotherapy\u00a0+ trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial","volume":"29","author":"Untch","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2014.06.004_bib41","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2- positive breast Cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.530","article-title":"Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study","volume":"29","author":"Loibl","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2014.06.004_bib43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"German breast group; Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie\u2013Breast study groups: neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2014.06.004_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","volume":"13","author":"Untch","year":"2012","journal-title":"Lancet Oncol"},{"issue":"Suppl.\u00a024","key":"10.1016\/j.breast.2014.06.004_bib45","first-page":"105s","article-title":"for the GBG and AGO-B study groups: neoadjuvant Chemotherapy of Paclitaxel with or without Rad001. Results of the NON- Responder Part of the GEPARQUINTO study (GBG 44)","volume":"71","author":"Huober","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2014.06.004_bib46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","article-title":"Bevacizumab added to neoadjuvant chemotherapy for breast Cancer","volume":"366","author":"Bear","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2014.06.004_bib47","series-title":"Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41","author":"Robidoux","year":"2012"},{"issue":"9816","key":"10.1016\/j.breast.2014.06.004_bib48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"issue":"Suppl.","key":"10.1016\/j.breast.2014.06.004_bib49","article-title":"The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)","volume":"72","author":"Piccart-Gebhart","year":"2012","journal-title":"Cancer Res"},{"issue":"suppl.","key":"10.1016\/j.breast.2014.06.004_bib50","volume":"32:5s","author":"Piccart-Gebhart","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.39.0823","article-title":"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2\u2013Positive operable breast Cancer: results of the randomized phase II CHER-LOB study","author":"Guarneri","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2014.06.004_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"24 Suppl.\u00a03","key":"10.1016\/j.breast.2014.06.004_bib53","article-title":"Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA)","volume":"71","author":"Schneeweiss","year":"2011","journal-title":"Cancer Res"},{"issue":"Suppl; abstr 1004","key":"10.1016\/j.breast.2014.06.004_bib54","article-title":"A\u00a0randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto \u2013 GBG 66)","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.breast.2014.06.004_bib55","article-title":"Impact of the addition of carboplatin (Cb) and\/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603","volume":"73","author":"Sikov","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2014.06.004_bib56","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","article-title":"Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks","volume":"23","author":"Green","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2014.06.004_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3816\/CBC.2010.n.011","article-title":"A\u00a0phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil\/epirubicin\/cyclophosphamide in locally advanced breast cancer","volume":"10","author":"Robidoux","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2014.06.004_bib58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1470-2045(13)70554-0","article-title":"Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial","volume":"15","author":"Earl","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2014.06.004_bib59","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2 positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.breast.2014.06.004_bib60","article-title":"Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4\/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+\/HER2\u2013 advanced breast cancer (BC)","volume":"72","author":"Finn","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2014.06.004_bib61","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.2010.31.8469","article-title":"Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"29","author":"Mittendorf","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977614001143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977614001143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:32:44Z","timestamp":1760776364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977614001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0960977614001143"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2014.06.004","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future role of neoadjuvant therapy for breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2014.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}